Artificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
Thomas Swalla
Advertisement
Articles by Thomas Swalla
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Study Claims Ozempic Lowers Biological Age
3
How will DTC Programs Impact PBMs?
4
GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate
5
